Perigon Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.08M Sell
29,481
-37,727
-56% -$1.79M 0.02% 510
2025
Q4
$3.42M Buy
67,208
+18,833
+39% +$963K 0.06% 264
2025
Q3
$2.68M Buy
48,375
+36,761
+317% +$2.15M 0.05% 292
2025
Q2
$802K Sell
11,614
-2,746
-19% -$187K 0.02% 538
2025
Q1
$997K Sell
14,360
-954
-6% -$78.8K 0.03% 452
2024
Q4
$1.27M Sell
15,314
-3,318
-18% -$359K 0.03% 388
2024
Q3
$2.22M Sell
18,632
-69
-0.4% -$9.2K 0.06% 271
2024
Q2
$2.67M Buy
18,701
+108
+0.6% +$14.3K 0.08% 220
2024
Q1
$2.39M Buy
18,593
+6,428
+53% +$765K 0.07% 229
2023
Q4
$1.26M Buy
12,165
+4,798
+65% +$474K 0.04% 295
2023
Q3
$670K Buy
7,367
+711
+11% +$62.6K 0.03% 384
2023
Q2
$539K Buy
6,656
+2,060
+45% +$168K 0.02% 439
2023
Q1
$366K Sell
4,596
-416
-8% -$29.5K 0.02% 475
2022
Q4
$339K Sell
5,012
-194
-4% -$11.4K 0.02% 496
2022
Q3
$259K Buy
5,206
+160
+3% +$8.57K 0.02% 465
2022
Q2
$281K Buy
+5,046
New +$280K 0.02% 440
2021
Q1
Sell
-1,360
Closed -$47K 853
2020
Q4
$47K Buy
+1,360
New +$47K 0.01% 759
2018
Q2
Sell
-1,050
Closed -$26K 485
2018
Q1
$26K Hold
1,050
0.01% 398
2017
Q4
$28K Hold
1,050
0.01% 364
2017
Q3
$25K Hold
1,050
0.01% 419
2017
Q2
$23K Sell
1,050
-3,482
-77% -$70.3K 0.01% 440
2017
Q1
$79K Sell
4,532
-1,530
-25% -$26.6K 0.02% 329
2016
Q4
$105K Buy
+6,062
New +$110K 0.02% 284
2016
Q3
Sell
-1,050
Closed -$28K 628
2016
Q2
$28K Buy
+1,050
New +$28.8K 0.01% 314

Other funds holding NVO

Perigon Wealth Management's NVO Position: Q1 2026 in Review

Perigon Wealth Management reduced its Novo Nordisk (NVO) stake by 56% in Q1 2026, selling an estimated $1.79M and leaving 29,481 shares worth $1.08M. The position accounts for 0.02% of the portfolio, ranked #510.

Perigon Wealth Management first reported a position in NVO in Q2 2016 and has held it in 24 quarters since. The position peaked at $3.42M in Q4 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Perigon Wealth Management held 29,481 shares of Novo Nordisk worth $1.08M as of Q1 2026.
  • Perigon Wealth Management sold 37,727 Novo Nordisk shares in Q1 2026, an estimated $1.79M.
  • Novo Nordisk made up 0.02% of Perigon Wealth Management's portfolio in Q1 2026, its #510 holding.
  • Perigon Wealth Management first reported a position in Novo Nordisk in Q2 2016 and has held it in 24 quarters since.
  • Perigon Wealth Management's Novo Nordisk position peaked at $3.42M in Q4 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Perigon Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.